source
- Enliven Therapeutics raises $400M as Jazz's Zepzelca misses confirmatory trialEnliven Therapeutics, a biotech based in Burlingame, California, announced that it priced a public offering of its common stock that raised about $400 million. The capital raise follows the compan…
- Novo's M&A head joins Forbion as Perrigo CEO steps down over conduct concernsNovo's senior M&A executive has left the company to take a role at Dutch investment firm Forbion. Forbion, which manages a portfolio of biotech companies, has been active in M&A and aims to increa…